Growth inhibitory efficacy and anti‑aromatase activity of Tabebuia avellanedae in a model for post‑menopausal Luminal A breast cancer

  • Authors:
    • Nitin Telang
    • Hareesh B. Nair
    • George Y.C. Wong
  • View Affiliations

  • Published online on: October 3, 2019     https://doi.org/10.3892/br.2019.1244
  • Pages: 222-229
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Aromatase inhibitors (AIs) represent a treatment option for post‑menopausal estrogen receptor‑positive (ER+) breast cancer as monotherapy, or in combination with cyclin‑dependent kinase 4/6 or mTOR inhibitors. Long‑term treatment with these agents leads to dose‑limiting toxicity and drug resistance. Natural substances provide testable alternatives to current therapy. Tabebuia avellanedae (TA) tree is indigenous to the Amazon rainforest. The inner bark of TA represents a medicinal dietary supplement known as Taheebo. Non‑fractionated aqueous extract from TA is an effective growth inhibitor in the Luminal A and triple negative breast cancer models. The quinone derivative naphthofurandione (NFD) is a major bioactive agent in TA. The present study examined the efficacy of finely ground powder from the inner bark of TA, available under the name of Taheebo‑NFD‑Marugoto (TNM). The ER+ MCF‑7 cells stably transfected with the aromatase gene MCF‑7AROM represented a model for aromatase‑expressing post‑menopausal breast cancer. Anchorage‑independent colony formation, cell cycle progression, pro‑apoptotic caspase 3/7 activity, apoptosis‑specific gene expression, aromatase activity and select estradiol (E2) target gene expression represented the mechanistic end points. Treatment of MCF‑7AROM cells with TNM induced a dose‑dependent reduction in E2‑promoted anchorage‑independent colony number. Mechanistic assays on TNM‑treated MCF‑7AROM cells demonstrated that TNM at a concentration of 10 µg (NFD content: 2 ng), induced S‑phase arrest, increased pro‑apoptotic caspase 3/7 activity, increased pro‑apoptotic BAX and decreased anti‑apoptotic BCL‑2 gene expression, and inhibited aromatase activity. Additionally, TNM treatment downregulated ESR‑1 (gene for ER‑α), aromatase and progesterone gene expression and reduced mRNA levels of E2 target genes pS2, GRB2 and cyclin D1. Inhibition of aromatase activity, based on the NFD content of TNM was superior to the clinical AIs Letrozole and Exemestane. These data demonstrated the potential efficacy of TNM as a nutritional alternative for current therapy of aromatase positive, post‑menopausal breast cancer.

Related Articles

Journal Cover

November 2019
Volume 11 Issue 5

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Telang, N., Nair, H.B., & Wong, G.Y. (2019). Growth inhibitory efficacy and anti‑aromatase activity of Tabebuia avellanedae in a model for post‑menopausal Luminal A breast cancer. Biomedical Reports, 11, 222-229. https://doi.org/10.3892/br.2019.1244
MLA
Telang, N., Nair, H. B., Wong, G. Y."Growth inhibitory efficacy and anti‑aromatase activity of Tabebuia avellanedae in a model for post‑menopausal Luminal A breast cancer". Biomedical Reports 11.5 (2019): 222-229.
Chicago
Telang, N., Nair, H. B., Wong, G. Y."Growth inhibitory efficacy and anti‑aromatase activity of Tabebuia avellanedae in a model for post‑menopausal Luminal A breast cancer". Biomedical Reports 11, no. 5 (2019): 222-229. https://doi.org/10.3892/br.2019.1244